Drug launches to watch in 2019

The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were

J&J earnings top expectations, but feels the squeeze in US

Nevertheless, the company's annual revenues rose almost 7% to $81.6bn, driven up by three rising star performers in particular: psoriasis treatment Stelara, leukaemia drug Imbruvica and multiple myeloma Darzalex.

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

Novartis’ Cosentyx can put some of its fast growth in psoriasis down to data showing it was more effective than Johnson &Johnson’s widely-used Stelara, but a new trial has ... In a head-to-head challenge, J&J’s recently approved follow-up to

New data keeps AbbVie’s star pipeline therapies on track

The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]